• Asia pacific journal of information systems
• /
• 제22권4호
• /
• pp.125-149
• /
• 2012

As the smart phone is propagating rapidly, the importance of mobile advertisement has also grown. One of the main characteristics of the Internet and smart phone advertising is that they can deliver personalized advertisements to each customer. The smart phone enables the identification of additional personalized information such as the customer's location and the accessibility to the site at any place any time. As the Internet platform becomes richer, firms that offer the ad services via the wired PC Internet and wireless smart phone are seeking various types of personalized ads. However, their service platform and Information and Communication Technology (ICT) platform should be suitable to the characteristics of personalized ads. This research explores various types of personalized ad methods and evaluates their adequacy encompassing four types of ad service platforms (such as search portal, news portal, e-mall servers, and SNS) and two types of ICT platforms (PC Internet and smart phone). To this end, we classified the personalized ads into seven types: three basic types and four composite types. The basic types of ad methods are identified by considering the current activity that the customer is engaged, the individual profile and log history, and the customer's current location or planning location. Four composite types of ad methods are constructed as the combination of these basic types. For those types of ad methods, we evaluate whether each ad method adequately maps with four types of ad service platforms and two types of ICT platforms. We proposed a metric of evaluation and demonstrated the concept with illustrative numbers. Specifically, we analyze and compare personalized ad methods in three ways. Firstly, the possibility of implementing a personalized ad method on the platform is analyzed to confirm the degree of suitability. Secondly, the value of personalized ad method is analyzed based on the customer accessibility. Lastly, expected effectiveness for each personalized ad method is computed by multiplying the possibility and the value. Through this kind of analysis, the ad service providers as well as advertising companies can evaluate what kinds of personalized ad methods and platforms are possible and suitable to maximize their ad effectiveness on the Internet and smart phone platforms.

• 산업진흥연구
• /
• 제9권3호
• /
• pp.13-25
• /
• 2024

본 연구는 디지털 시대에 개인화 광고의 발전과 함께 발생한 개인정보 우려 및 광고 짜증과 같은 부정적 감정이 구매 의도에 미치는 영향에 관해 연구하고자 하였다. 연구 결과 개인정보 우려는 광고 회피에 유의미한 영향을 미치지 않았으나 광고 짜증과 브랜드 회피에는 유의미한 영향을 미쳤다. 광고 짜증은 광고 회피에 유의미한 영향을 미쳤으나 브랜드 회피나 구매 의도에는 영향을 미치지 않았다. 광고 회피는 브랜드 회피에 유의미한 영향을 미쳤으며, 광고 회피와 브랜드 회피 모두 구매 의도에 유의미한 부정적 영향을 미쳤다. 그리고 광고 짜증은 개인정보 우려와 광고 회피 사이를 완전히 매개하지만, 개인정보 우려와 브랜드 회피 사이에서는 그렇지 않았다. 광고 회피는 광고 짜증과 구매 의도 사이를 완전히 매개하지만, 브랜드 회피는 광고 자극과 구매 의도 사이의 관계에 유의미한 영향을 미치지 않았다. 이러한 연구 결과는 MZ세대의 특성을 고려할 때 나타나는 현상으로, 더 다양한 연구의 필요성을 시사한다.

• 대한치매학회지
• /
• 제23권4호
• /
• pp.188-201
• /
• 2024

Alzheimer's disease (AD), a leading cause of dementia, presents a formidable global health challenge intensified by the aging population. This review encapsulates the evolving landscape of AD diagnosis and treatment with a special focus on the innovative role of fluid biomarkers. Pathologically, AD is marked by amyloid beta (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau, which lead to synaptic dysfunction, neuronal loss, and cognitive decline. These pathological changes, commencing decades before symptom onset, underscore the need for early detection and intervention. Diagnosis traditionally relies on clinical assessment, neuropsychological testing, and neuroimaging techniques. However, fluid biomarkers in cerebrospinal fluid and blood, such as various forms of Aβ, total tau, phosphorylated tau, and neurofilament light chain, are emerging as less invasive, cost-effective diagnostic tools. These biomarkers are pivotal for early diagnosis, differential diagnosis, disease progression monitoring, and treatment response evaluation. The treatment landscape is shifting toward personalized medicine, highlighted by advancements in Aβ immunotherapies, such as lecanemab and donanemab. Demonstrating efficacy in phase III clinical trials, these therapies hold promise as tailored treatment strategies based on individual biomarker profiles. The integration of fluid biomarkers into clinical practice represents a significant advance in AD management, providing the potential for early and precise diagnosis, coupled with personalized therapeutic approaches. This heralds a new era in combating this debilitating disease.

• KSII Transactions on Internet and Information Systems (TIIS)
• /
• 제19권8호
• /
• pp.2427-2460
• /
• 2025

Early detection, particularly during the mild cognitive impairment (MCI) stages, provides an important opportunity for intervention. Recently, deep learning models have leveraged these Region of Interest (ROIs) from functional MRI (fMRI) to construct and represent the Brain network. However, recent deep learning models primarily capture local brain regions, limiting their ability to represent distant and global features. Constructing effective brain connectivity graphs that balance spatial correlations, and temporal information remains a challenge for Alzheimer's Disease (AD) diagnosis. To address these limitations, we propose the Hierarchical-Spatio-Temporal Graph Convolutional Network (Hi-STGCN), a novel deep learning framework designed to enhance AD classification. Hi-STGCN follows a two-tier hierarchical structure: first, it constructs Masked Spatio-Temporally Updated Brain networks (MSTUB) to refine features at the subject level by leveraging region-wise spatiotemporal dependencies. Then, a Population Network integrates these representations across multiple subjects, capturing global connectivity patterns that improve classification robustness. With classification accuracies of 95.95% (AD vs. CN), 93.65% (AD vs. MCI), and 92.16% (MCI vs. CN), Hi-STGCN outperforms existing models, demonstrating its potential in advancing early diagnosis and personalized treatment strategies for AD.

• 대한치매학회지
• /
• 제24권2호
• /
• pp.75-90
• /
• 2025

Alzheimer's disease (AD), a neurodegenerative disorder characterized by the accumulation of amyloid-beta plaques and tau tangles, shows cognitive decline. Recent genetic studies have identified over 30 variants that are resilient to AD pathology, offering new therapeutic opportunities. This review explores key protective mutations of APOE3 Christchurch, RELN-COLBOS, FN1, APP A673T, BDNF Val66Met, SORL1, CR1, TREM2, PICALM, and INPP5 D genes. These affect critical pathways, including lipid metabolism, synaptic function, tau regulation, and immune response. Potential treatments are discussed, including gene therapy and neuroprotective strategies, emphasizing a shift toward precision medicine focused on genetic resilience. By reviewing case studies and relevant literatures, the work explores the mechanisms by which these variants mitigate amyloid accumulation, tau pathology, neurodegeneration, and neuroinflammation, the key contributors to AD progression. Understanding these protective pathways offers critical insights into potential therapeutic applications, such as gene therapy, immune-modulating treatments, and personalized medicine approaches tailored to the individual's genetic profile. The findings highlight the potential to leverage genetic protection mechanisms to develop precision interventions for AD, offering new hope to prevent or delay disease onset and progression. These discoveries could transform future treatment strategies, shifting the focus from risk management to exploiting genetic resilience to combat AD.

• 디지털융복합연구
• /
• 제12권4호
• /
• pp.183-192
• /
• 2014

본 연구는 모바일 미디어를 통하여 나타나는 확장된 개인의 자아 형성을 여러 관점에서 다양하게 논의하고자 한다. 구체적으로 모바일 미디어의 개인적 특성과 사회적 특성에 따라 모바일 광고 수용에 영향을 미치는 정도를 실증적으로 밝히고자 한다. 특히 주목할 점은 개인이 자신만을 위한 모바일 기기를 소유함으로서 소유인식이나 자아에 영향을 주는 개인의 사회적 차원에 주목하고자 한다. 연구결과 모바일 미디어 사용에서 개인적 이용특성과 사회적 이용 특성과정을 고려할 필요가 있음을 밝혔으며, 가설 검증 결과 모바일의 이용으로 발생하는 사회적 특성과 개인적 특성이 광고인식에 큰 영향을 주는 것으로 나타났으며, 사회적 특성이 보다 개인적 특성이 상대적으로 영향력을 더 미치는 것으로 나타났다. 이는 광고인식의 발생에 있어서 기능중심의 개인적 특징이 광고에 대한 지각이나 노출이라는 측면에서 영향력이 큰 반면 사회적 특징과 관계적 특징이 향 후 내면적 인식에 따른 상호작용성에 중요한 역할을 함을 시사하고 있다.

• 디지털융복합연구
• /
• 제17권2호
• /
• pp.81-89
• /
• 2019

본 연구는 페이스북 광고의 구성요인이 광고적절성 인식과 구전의도에 미치는 영향을 알아보았다. 부가적으로 광고 적절성 인식의 매개효과를 확인하였다. 이를 위해 페이스북 사용자를 대상으로 371개 자료를 수집하였다. 연구방법은 요인 분석과 공변량구조분석을 활용하였다. 연구결과 첫째, 페이스북 광고의 광고흥미성 속성은 광고적절성 인식과 구전의도에 유의미한 영향을 미쳤다. 둘째, 페이스북 광고의 맞춤정보성 속성은 광고적절성 인식과 구전의도에 유의미한 영향을 미쳤다. 셋째, 주변인반응성 속성은 광고적절성 인식과 구전의도에 유의미한 영향을 미쳤다. 넷째, 페이스북 광고적절성 인식은 구전 의도에 유의미한 영향을 미쳤다. 따라서 광고흥미성과 맞춤정보성 및 주변인반응성 속성은 완전매개효과를 나타냈다. 이러한 연구결과는 소비자들에게 페이스북 광고로서 정체감이 있는 광고와 효과적인 광고를 제작할 때 고려해야할 속성이 무엇인가에 대한 자료를 제공할 것이다.

• International Journal of Stem Cells
• /
• 제18권3호
• /
• pp.263-274
• /
• 2025

Alcohol dependence (AD) is one of the most prevalent neuropsychiatric disorders. Multiple polymorphisms in the Fyn tyrosine kinase gene (FYN) were found to be associated with AD. The function of AD-associated FYN variants remains largely unknown due to the absence of an appropriate model for studying them. Here, we generated human embryonic stem cell lines homozygous/heterozygous for rs706895 C/T alleles in 5' untranslated region (5' UTR) of FYN by CRISPR-Cas9 editing to explore the AD association. Transcriptome and reporter gene analyses demonstrated that induced neurons with the rs706895 C allele showed a significantly higher expression level of FYN under ethanol treatment. Our results suggest that FYN 5' UTR variant rs706895 may influence an individual's vulnerability to AD by altering FYN expression. Targeting AD-associated variants may provide a better understanding of disease mechanisms and a reliable basis for the personalized AD treatment.

• 노인정신의학
• /
• 제16권1호
• /
• pp.17-23
• /
• 2012

The diagnosis of Alzheimer's disease (AD) is still obscure even to specialists. To improve the diagnostic accuracy, to find at-risk people as early as possible, to predict the efficacy or adverse reactions of pharmacotherapy on an individual basis, to attain more reliable results of clinical trials by recruiting better defined participants, to prove the disease-modifying ability of new candidate drugs, to establish prognosis-based therapeutic plans, and to do more, is now increasing the need for biomarkers for AD. Among AD-related biochemical markers, cerebrospinal beta-amyloid and tau have been paid the most attention since they are materials directly interfacing the brain interstitium and can be obtained through the lumbar puncture. Level of beta-amyloid is reduced whereas tau is increased in cerebrospinal fluid of AD patients relative to cognitively normal elderly people. Remarkably, such information has been found to help predict AD conversion of mild cognitive impairment. Despite inconsistent findings from previous studies, plasma beta-amyloid is thought to be increased before the disease onset, but show decreasing change as the disease progress. Regarding other peripheral biochemical markers, omics tools are being widely used not only to find useful biomarkers but also to generate novel hypotheses for AD pathogenesis and to lead new personalized future medicine.

• Biomolecules & Therapeutics
• /
• 제33권5호
• /
• pp.813-829
• /
• 2025

Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder characterized by pruritus, skin barrier dysfunction, and immune dysregulation. It significantly impacts the quality of life and increases the risk of infections, sleep disturbances, and psychological distress. AD pathogenesis involves genetic predisposition, environmental triggers, microbiome alterations, and immune dysfunction. Traditional treatments such as topical corticosteroids, calcineurin inhibitors, and systemic immunosuppressants provide symptomatic relief but often fail to provide long-term disease control. The emergence of targeted biologics and Janus kinase inhibitors has transformed AD management by offering more precise and effective therapeutic options. However, treatment responses vary, highlighting the need for biomarker-driven personalized therapies. In this review, we explore the evolving therapeutic landscape of AD, emphasizing the emerging role of biomarker-guided treatment strategies. We highlight recent discoveries of therapeutic (OX40, IgE, IL-5, IL-31, IL-22, thymic stromal lymphopoietin) and diagnostic (TARC/CCL17, MDC/CCL2, filaggrin, sphingosine-1-phosphate, CXCL2) biomarkers that offer promising avenues for patient stratification and treatment monitoring. This review offers novel insight into how the convergence of biomarker research and therapeutic innovation can address current gaps in AD care. Future research should focus on refining biomarker-guided treatment strategies, optimizing therapeutic combinations, and addressing unmet patient needs. The integration of biomarker-guided strategies into routine clinical practice represents a critical step toward long-term disease control and improved quality of life for AD patients.